P&F Products and Features GmbH, the Austria-based cardiovascular device innovator, has secured approval from the U.S. Food and Drug Administration to initiate the TRICAV II pivotal clinical trial. The study will evaluate the TricValve Transcatheter Bicaval Valve System for severe tricuspid regurgitation, aiming to provide a minimally invasive option for patients who currently have no […]
FDA re-approves Augmentin XR under new priority program, restoring key antibiotic and signaling a turning point in U.S. drug supply strategy. Read more.
ProVerum wins FDA approval for ProVee, a permanent urethral stent for BPH offering fast recovery and no catheter. See how it could disrupt the urology device market.
Lilly’s Jaypirca met its Phase 3 target in CLL, matching Imbruvica on response rate and showing superior safety. Could this rewire frontline BTK therapy?